To investigate the potential role of these receptors in antagonizing the effects of TRAIL-R1 and -R2, additional analyses were performed and TRAIL-R3 and TRAIL-R4 staining in tumor samples of our patients’ collective assessed. This evidence concerns the gene TNFRSF10A and neoplasm.